356 related articles for article (PubMed ID: 33994322)
1. The challenge of emerging SARS-CoV-2 mutants to vaccine development.
Li R; Liu J; Zhang H
J Genet Genomics; 2021 Feb; 48(2):102-106. PubMed ID: 33994322
[No Abstract] [Full Text] [Related]
2. COVID-19 vaccine breakthrough infections.
Gupta RK; Topol EJ
Science; 2021 Dec; 374(6575):1561-1562. PubMed ID: 34941414
[TBL] [Abstract][Full Text] [Related]
3. Variant-proof vaccines - invest now for the next pandemic.
Burton DR; Topol EJ
Nature; 2021 Feb; 590(7846):386-388. PubMed ID: 33558746
[No Abstract] [Full Text] [Related]
4. The emerging plasticity of SARS-CoV-2.
McCormick KD; Jacobs JL; Mellors JW
Science; 2021 Mar; 371(6536):1306-1308. PubMed ID: 33766871
[No Abstract] [Full Text] [Related]
5. SARS-CoV-2 evolution and vaccines: cause for concern?
Williams TC; Burgers WA
Lancet Respir Med; 2021 Apr; 9(4):333-335. PubMed ID: 33524316
[No Abstract] [Full Text] [Related]
6. Sieve analysis to understand how SARS-CoV-2 diversity can impact vaccine protection.
Rolland M; Gilbert PB
PLoS Pathog; 2021 Mar; 17(3):e1009406. PubMed ID: 33765086
[No Abstract] [Full Text] [Related]
7. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.
Wang P; Nair MS; Liu L; Iketani S; Luo Y; Guo Y; Wang M; Yu J; Zhang B; Kwong PD; Graham BS; Mascola JR; Chang JY; Yin MT; Sobieszczyk M; Kyratsous CA; Shapiro L; Sheng Z; Huang Y; Ho DD
Nature; 2021 May; 593(7857):130-135. PubMed ID: 33684923
[TBL] [Abstract][Full Text] [Related]
8. Fast-spreading COVID variant can elude immune responses.
Callaway E
Nature; 2021 Jan; 589(7843):500-501. PubMed ID: 33479534
[No Abstract] [Full Text] [Related]
9. Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies.
Collier DA; De Marco A; Ferreira IATM; Meng B; Datir RP; Walls AC; Kemp SA; Bassi J; Pinto D; Silacci-Fregni C; Bianchi S; Tortorici MA; Bowen J; Culap K; Jaconi S; Cameroni E; Snell G; Pizzuto MS; Pellanda AF; Garzoni C; Riva A; ; Elmer A; Kingston N; Graves B; McCoy LE; Smith KGC; Bradley JR; Temperton N; Ceron-Gutierrez L; Barcenas-Morales G; ; Harvey W; Virgin HW; Lanzavecchia A; Piccoli L; Doffinger R; Wills M; Veesler D; Corti D; Gupta RK
Nature; 2021 May; 593(7857):136-141. PubMed ID: 33706364
[TBL] [Abstract][Full Text] [Related]
10. COVID-19 mRNA vaccines.
Huang Q; Zeng J; Yan J
J Genet Genomics; 2021 Feb; 48(2):107-114. PubMed ID: 34006471
[TBL] [Abstract][Full Text] [Related]
11. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD
Elife; 2020 Oct; 9():. PubMed ID: 33112236
[TBL] [Abstract][Full Text] [Related]
12. Mutation-induced changes in the receptor-binding interface of the SARS-CoV-2 Delta variant B.1.617.2 and implications for immune evasion.
Baral P; Bhattarai N; Hossen ML; Stebliankin V; Gerstman BS; Narasimhan G; Chapagain PP
Biochem Biophys Res Commun; 2021 Oct; 574():14-19. PubMed ID: 34425281
[TBL] [Abstract][Full Text] [Related]
13. Omicron (B.1.1.529) - variant of concern - molecular profile and epidemiology: a mini review.
Kannan S; Shaik Syed Ali P; Sheeza A
Eur Rev Med Pharmacol Sci; 2021 Dec; 25(24):8019-8022. PubMed ID: 34982466
[TBL] [Abstract][Full Text] [Related]
14. Symptomatic reinfection of SARS-CoV-2 with spike protein variant N440K associated with immune escape.
Rani PR; Imran M; Lakshmi JV; Jolly B; Jain A; Surekha A; Senthivel V; Chandrasekhar P; Divakar MK; Srinivasulu D; Bhoyar RC; Vanaja PR; Scaria V; Sivasubbu S
J Med Virol; 2021 Jul; 93(7):4163-4165. PubMed ID: 33818797
[No Abstract] [Full Text] [Related]
15. Will SARS-CoV-2 variants of concern affect the promise of vaccines?
Gupta RK
Nat Rev Immunol; 2021 Jun; 21(6):340-341. PubMed ID: 33927376
[TBL] [Abstract][Full Text] [Related]
16. Implication of SARS-CoV-2 Immune Escape Spike Variants on Secondary and Vaccine Breakthrough Infections.
Ahmad L
Front Immunol; 2021; 12():742167. PubMed ID: 34804022
[TBL] [Abstract][Full Text] [Related]
17. How to redesign COVID vaccines so they protect against variants.
Callaway E; Ledford H
Nature; 2021 Feb; 590(7844):15-16. PubMed ID: 33514888
[No Abstract] [Full Text] [Related]
18. SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants.
MartÃnez-Flores D; Zepeda-Cervantes J; Cruz-Reséndiz A; Aguirre-Sampieri S; Sampieri A; Vaca L
Front Immunol; 2021; 12():701501. PubMed ID: 34322129
[TBL] [Abstract][Full Text] [Related]
19. SARS-CoV-2 B.1.617 Mutations L452R and E484Q Are Not Synergistic for Antibody Evasion.
Ferreira IATM; Kemp SA; Datir R; Saito A; Meng B; Rakshit P; Takaori-Kondo A; Kosugi Y; Uriu K; Kimura I; Shirakawa K; Abdullahi A; Agarwal A; Ozono S; Tokunaga K; Sato K; Gupta RK; ;
J Infect Dis; 2021 Sep; 224(6):989-994. PubMed ID: 34260717
[TBL] [Abstract][Full Text] [Related]
20. Heavily mutated Omicron variant puts scientists on alert.
Callaway E
Nature; 2021 Dec; 600(7887):21. PubMed ID: 34824381
[No Abstract] [Full Text] [Related]
[Next] [New Search]
